Cristina Vaghi

Cristina Vaghi

Auto-generated profile, based on publicly available information

Cristina Vaghi

Inria Team MONC Inria Bordeaux Sud-Ouest Talence France

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 February 2020 in PLOS Computational Biology
Verified
Journal Article
Open access
PDF file
CVCristina Vaghi
Cristina Vaghi
ARAnne Rodallec
Anne Rodallec
RFRaphaëlle Fanciullino
Raphaëlle Fanciullino
Joseph CiccoliniJoseph Ciccolini
Joseph Ciccolini
Jonathan MochelJonathan Mochel
Jonathan Mochel
SBSebastien Benzekry
Sebastien Benzekry
Tumor growth curves are classically modeled by means of ordinary differential equations. In analyzing the Gompertz model several studies have reported a striking correlation between the two parameters of the model, which could be used to reduce the dimensionality and improve predictive power. We analyzed tumor growth kinetics within the statistical framework of nonlinear mixed-effects (population approach). This allowed the simultaneous modeling of tumor dynamics and inter-animal variability. Experimental data comprised three animal models of breast and lung cancers, with 833 measurements in 94 animals. Candidate models of tumor growth included the exponential, logistic and Gompertz models. The exponential and—more notably—logistic models failed to describe the experimental data whereas the Gompertz model generated very good fits. The previously reported population-level correlation between the Gompertz parameters was further confirmed in our analysis (R2> 0.92 in all groups). Combining this structural correlation with rigorous population parameter estimation, we propose a reduced Gompertz function consisting of a single individual parameter (and one population parameter). Leveraging the population approach using Bayesian inference, we estimated times of tumor initiation using three late measurement timepoints. The reduced Gompertz model was found to exhibit the best results, with drastic improvements when using Bayesian inference as compared to likelihood maximization alone, for both accuracy and precision. Specifically, mean accuracy (prediction error) was 12.2% versus 78% and mean precision (width of the 95% prediction interval) was 15.6 days versus 210 days, for the breast cancer cell line. These results demonstrate the superior predictive power of the reduced Gompertz model, especially when combined with Bayesian estimation. They offer possible clinical perspectives for personalized prediction of the age of a tumor from limited data at diagnosis. The code and data used in our analysis are publicly available at https://github.com/cristinavaghi/plumky. Mathematical models for tumor growth kinetics have been widely used since several decades but mostly fitted to individual or average growth curves. Here we compared three classical models (exponential, logistic and Gompertz) using a population approach, which accounts for inter-animal variability. The exponential and the logistic models failed to fit the experimental data while the Gompertz model showed excellent descriptive power. Moreover, the strong correlation between the two parameters of the Gompertz equation motivated a simplification of the model, the reduced Gompertz model, with a single individual parameter and equal descriptive power. Combining the mixed-effects approach with Bayesian inference, we predicted the age of individual tumors with only few late measurements. Thanks to its simplicity, the reduced Gompertz model showed superior predictive power. Although our method remains to be extended to clinical data, these results are promising for the personalized estimation of the age of a tumor from limited measurements at diagnosis.

30 April 2024 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
PDF file
MDMelissa Dolan
Melissa Dolan
YSYuhao Shi
Yuhao Shi
MMMichalis Mastri
Michalis Mastri
MLMark Long
Mark Long
AMAmber McKenery
Amber McKenery
JEJohn M. L. Ebos
John M. L. Ebos
Tyrosine kinase inhibitors (TKIs) that block the vascular endothelial growth factor receptors (VEGFRs) not only disrupt tumor angiogenesis but also have many unexpected side effects that impact tumor cells directly. This includes the induction of molecular markers associated with senescence, a form of cellular aging that typically involves growth arrest. We have shown that VEGFR TKIs can hijack these aging programs by transiently inducting senescence markers (SMs) in tumor cells to activate senescence-associated secretory programs that fuel drug resistance. Here we show that these same senescence-mimicking (“senomimetic”) VEGFR TKI effects drive an enhanced immunogenic signaling that, in turn, can alter tumor response to immunotherapy. By using a live cell sorting method to detect β-galactosidase, a commonly used SM, we found that subpopulations of SM-expressing (SM+) tumor cells have heightened IFN signaling and increased expression of IFN-stimulated genes (ISGs). These ISGs increase under the control of the STimulator of the INterferon Gene (STING) signaling pathway, which we found could be directly activated by several VEGFR TKIs. TKI-induced SM+ cells could stimulate or suppress CD8 T-cell activation depending on host–tumor cell contact while tumors grown from SM+ cells were more sensitive to PDL1 inhibition in vivo, suggesting that offsetting immune-suppressive functions of SM+ cells can improve TKI efficacy overall. Our findings may explain why some (but not all) VEGFR TKIs improve outcomes when combined with immunotherapy and suggest that exploiting senomimetic drug side effects may help identify TKIs that uniquely “prime” tumors for enhanced sensitivity to PDL1-targeted agents.

13 June 2019 in bioRxiv
Verified
Preprint
Open access
PDF file
CVCristina Vaghi
Cristina Vaghi
ARanne rodallec
anne rodallec
RFRaphaelle Fanciullino
Raphaelle Fanciullino
Joseph CiccoliniJoseph Ciccolini
Joseph Ciccolini
Jonathan MochelJonathan Mochel
Jonathan Mochel
SBSebastien Benzekry
Sebastien Benzekry
Tumor growth curves are classically modeled by ordinary differential equations. In analyzing the Gompertz model several studies have reported a striking correlation between the two parameters of the model. We analyzed tumor growth kinetics within the statistical framework of nonlinear mixed-effects (population approach). This allowed for the simultaneous modeling of tumor dynamics and interanimal variability. Experimental data comprised three animal models of breast and lung cancers, with 843 measurements in 94 animals. Candidate models of tumor growth included the Exponential, Logistic and Gompertz. The Exponential and – more notably – Logistic models failed to describe the experimental data whereas the Gompertz model generated very good fits. The population-level correlation between the Gompertz parameters was further confirmed in our analysis (R 2 > 0.96 in all groups). Combining this structural correlation with rigorous population parameter estimation, we propose a novel reduced Gompertz function consisting of a single individual parameter. Leveraging the population approach using bayesian inference, we estimated the time of tumor initiation using three late measurement timepoints. The reduced Gompertz model was found to exhibit the best results, with drastic improvements when using bayesian inference as compared to likelihood maximization alone, for both accuracy and precision. Specifically, mean accuracy was 12.1% versus 74.1% and mean precision was 15.2 days versus 186 days, for the breast cancer cell line. These results offer promising clinical perspectives for the personalized prediction of tumor age from limited data at diagnosis. In turn, such predictions could be helpful for assessing the extent of invisible metastasis at the time of diagnosis. Author summary: Mathematical models for tumor growth kinetics have been widely used since several decades but mostly fitted to individual or average growth curves. Here we compared three classical models (Exponential, Logistic and Gompertz) using a population approach, which accounts for inter-animal variability. The Exponential and the Logistic models failed to fit the experimental data while the Gompertz model showed excellent descriptive power. Moreover, the strong correlation between the two parameters of the Gompertz equation motivated a simplification of the model, the reduced Gompertz model, with a single individual parameter and equal descriptive power. Combining the mixed-effects approach with Bayesian inference, we predicted the age of individual tumors with only few late measurements. Thanks to its simplicity, the reduced Gompertz model showed superior predictive power. Although our method remains to be extended to clinical data, these results are promising for the personalized estimation of the age of a tumor from limited measurements at diagnosis. Such predictions could contribute to the development of computational models for metastasis.

9 June 2020 in ESAIM: Proceedings and Surveys
Verified
Journal Article
Open access
PDF file
JGJérôme Gilleron
Jérôme Gilleron
TGThierry GOUDON
Thierry GOUDON
FLFrédéric Lagoutière
Frédéric Lagoutière
HMHugo Martin
Hugo Martin
BMBenjamin Mauroy
Benjamin Mauroy
CVCristina Vaghi
Cristina Vaghi
We propose in this article a model describing the dynamic of a system of adipocytes, structured by their sizes. This model takes into account the differentiation of a population of mesenchymal cells into preadipocytes and of preadipocytes into adipocytes; the differentiation rates depend on the mean adipocyte radius. The considered equations are therefore ordinary differential equations, coupled with an advection equation, the growth rate of which depends on food availability and on the total surface of adipocytes. Since this velocity is discontinuous, we need to introduce a convenient notion of solutions coming from Filippov theory. We are consequently able to determine the stationary solutions of the system, to prove the existence and uniqueness of solutions and to describe the asymptotic behavior of solutions in some simple cases. Finally, the parameters of the model are fitted thanks to some experimental data and numerical simulations are displayed; a spatial extension of the model is studied numerically. Nous proposons dans cet article un modèle décrivant la dynamique d’un ensemble d’adipocytes structurés en taille. Ce modèle tient compte de la différentiation d’une population de cellules mésenchymales en préadipocytes et des préadipocytes en adipocytes; les taux de différentiation dépendent du rayon moyen des adipocytes. Les équations considérées sont, par conséquence, des équations différentielles ordinaires, couplées avec une équation d’advection, dont le taux de croissance dépend de la nourriture disponible et de la surface totale des adipocytes. Comme la vitesse est discontinue, nous introduisons une notion appropriée des solutions, provenant de la théorie de Filippov. Nous sommes alors en mesure de déterminer les solutions stationnaires du système, de prouver l’existence et l’unicité de solutions et de décrire le comportement asymptotique des solutions dans certains cas simples. Finalement, les paramètres du modèles sont estimés grâce à des données expérimentales et des simulations numériques sont présentées; une extension spatiale du modèles est étudiée numériquement.

3 July 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
CVCristina Vaghi
Cristina Vaghi
RFRaphaelle Fanciullino
Raphaelle Fanciullino
SBSebastien Benzekry
Sebastien Benzekry
CPClair Poignard
Clair Poignard
Understanding the dynamics underlying fluid transport in tumour tissues is of fundamental importance to assess processes of drug delivery. Here, we analyse the impact of the tumour microscopic properties on the macroscopic dynamics of vascular and interstitial fluid flow by using formal asymptotic techniques. Here, we obtained different macroscopic continuum models that couple vascular and interstitial flows. The homogenization technique allows us to derive two macroscale tissue models of fluid flow that take into account the microscopic structure of the vessels and the interstitial tissue. Different regimes were derived according to the magnitude of the vessel wall permeability and the interstitial hydraulic conductivity. Importantly, we provide an analysis of the properties of the models and show the link between them. Numerical simulations were eventually performed to test the models and to investigate the impact of the microstructure on the fluid transport. Future applications of our models include their calibration with real imaging data to investigate the impact of the tumour microenvironment on drug delivery.

4 September 2024
Verified
Other
Open access
PDF file
MDMelissa Dolan
Melissa Dolan
YSYuhao Shi
Yuhao Shi
MMMichalis Mastri
Michalis Mastri
MLMark Long
Mark Long
AMAmber McKenery
Amber McKenery
JEJohn M.L. Ebos
John M.L. Ebos
Figure S1: Extended data for Fig 1 - Enriched IFN signaling in SM+ tumor cells after VEGFR TKI treatment. (A) In vivo derivation of 4T1AxR lung metastasis taken from mice after surgical resection of orthotopically implanted 4T1 cells and following Ax treatment (100mg/kg/day). Described in 7. (B) Proliferation analysis of 4T1 cells after treatment with multiple VEGFR TKIs. IC50 values indicated in red. (MTS assay; n = 3-4) (C) In vivo derivation of a Ca-resistant mouse breast tumor cell line EMT6 (EMT6CaR) and vehicle-treated control (EMT6M) taken from lung metastasis of Balb/c mice after orthotopic implantation of EMT6 and following Ca (30mg/kg/day) or vehicle treatment. (D-E) EMT6CaR cells showed increases (compared to EMT6M controls) in D) SM expression (by flow cytometry; n=6) and E) ISG expression (by qRT-PCR; n=3). (F) Proliferation analysis of EMT6M cells after Ca and Ax treatment to choose optimal dosing. IC50 values indicated in red. (MTS assay; n = 3-4) (G-I) SM expression after Ax or Ca treatment in (F) EMT6M, (G) RENCA, and (H) LM2-4 cells (flow cytometry; n=3-6). (J-L) ISG expression after Ca treatment in (I) EMT6M, (J) 4T1, and (K) LM2-4 cells (qRT-PCR; n=3). (M) ISG expression after Ax treatment in EMT6M cells (qRT-PCR; n=3). Parental (P), Axitinib (Ax), Cabozantinib (Ca), Short-term (ST), Vehicle (Veh), Fold Change (FC); Interferon-stimulated genes (ISGs); 5-Dodecanoylaminofluorescein Di-β-D-Galactopyranoside (C12FDG); Standard deviation (SD); Drug concentration for Ax (0.5µM for F and L; 2µM for G and K) and Ca (2µM for F, G, I and J; 5µM for H and K); #, indicates experiment terminated. Quantitative data is shown as mean ± SD; * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001.